TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22484576

Group type: EXPERIMENTAL
Intervention: FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by DOC (3 courses of docetaxel 100 mg/m(2))
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DOC (3 courses of docetaxel 100 mg/m(2)) followed by FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2))
Number of subjects: 42
Study: 21852678

Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring (BGM)
Number of subjects: 72
Study: 19436696

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 137

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 137
Study: 16923097

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg, Midazolam 0.03 mg/kg, Propofol 2.5 mg/kg (group FMP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg, Lignocaine 1.5 mg/kg, Propofol 2.5 mg/kg (group FLP)
Number of subjects: 80
Study: 12784100

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg q.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined regimens of Duloxetine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desipramine 50 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duloxetine and Desipramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10864586

Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg priming dose + 3 mg/kg per h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HOI superimposed on L‐NMMA infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo infusion (time control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HOI without L‐NMMA infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 7
Study: 8875556

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol acetate (125 mg/g) applied twice daily for three months
Number of subjects: 19

Group type: COMPARATOR
Intervention: difluoromethylornithine cream applied twice daily for three months
Number of subjects: 19
Study: 1843365

Group type: EXPERIMENTAL
Intervention: Quassia Amarga (alcoholic solution)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 6470621

Group type: EXPERIMENTAL
Intervention: human‐film aggression
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: cartoon‐film aggression
Number of subjects: 96

Group type: COMPARATOR
Intervention: neutral film
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: real‐life (act of war) aggression
Number of subjects: 96
Study: 30797257

Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2) dentifrice (Colgate TotalSF) stabilized with zinc phosphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 100
Study: 29518094

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin lispro infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Once-daily insulin isophane
Number of subjects: 24
Study: 26682871

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the low-risk group (GH >67)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the intermediate-risk group (46 ≤ GH ≤ 67)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy in the high-risk group (GH <46)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Global health status (GH) score at baseline
Number of subjects: 451
Study: 24456362

Group type: EXPERIMENTAL
Intervention: Doenjang (9.8 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22621409

Group type: EXPERIMENTAL
Intervention: Spaced education group
Number of subjects: 42
Study: 20698962

Group type: EXPERIMENTAL
Intervention: Kopstoring intervention (online intervention for COPMI-children)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Waiting list care as usual (control group)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Kopstoring intervention (extended measure at 12 months)
Number of subjects: 214
Study: 17931765

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single Bond
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clearfil Tri S Bond
Number of subjects: 48
Study: 15775733

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) 0.625 mg conjugated equine estrogens (CEE) combined with 2.5 mg medroxyprogesterone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of HRT and Simvastatin (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simvastatin (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11934159

Group type: EXPERIMENTAL
Intervention: Local motion detectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global motion detectors
Number of subjects: 0
Study: 10559578

Group type: EXPERIMENTAL
Intervention: 0.1% budesonide in Finn Chambers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: budesonide‐printed polyester squares in serial doses (150‐0.074 microg/cm(2))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doubtful or weakly visible reactivity at the test edges assessed by test perfusion assessments
Number of subjects: 10
Study: 7586263

Group type: EXPERIMENTAL
Intervention: 80-cc can size
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60-cc can size
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40-cc can size
Number of subjects: 24
Study: 2122037

Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 0
Study: 204248

Group type: EXPERIMENTAL
Intervention: 0.02% solution of prodigiosan administered intranasally (0.2 ml once every 4 days for 4 months)
Number of subjects: 0
Study: 31136233

Group type: EXPERIMENTAL
Intervention: Barium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blue Dye
Number of subjects: 30

Group type: COMPARATOR
Intervention: Green Dye
Number of subjects: 30
Study: 27859471

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No soft tissue grafting (control)
Number of subjects: 17
Study: 25095746

Group type: EXPERIMENTAL
Intervention: Circulating TNF‐α
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Circulating CRP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Circulating sICAM
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Circulating IL‐6
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gene expression of IL‐6
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gene expression of CD36
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gene expression of TNF‐α
Number of subjects: 75
Study: 23587440

Group type: EXPERIMENTAL
Intervention: Winning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losing
Number of subjects: 0
Study: 21422866

Group type: EXPERIMENTAL
Intervention: Vaginal pH-balanced gel (administered three times per week for 12 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (administered three times per week for 12 weeks)
Number of subjects: 86
Study: 19363969

Group type: EXPERIMENTAL
Intervention: Three 15-minute in-office bleaching treatments with 36% hydrogen peroxide followed by at-home overnight bleaching with 15% carbamide peroxide for seven days.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 40-minute in-office bleaching treatment followed by at-home overnight bleaching for seven days.
Number of subjects: 37

Group type: COMPARATOR
Intervention: In-office treatment without at-home bleaching.
Number of subjects: 37
Study: 17466675

Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 35
Study: 15226561

Group type: EXPERIMENTAL
Intervention: Cefpodoxime 5 mg/kg b.i.d. for 10-14 days
Number of subjects: 776

Group type: COMPARATOR
Intervention: Cefixime 4 mg/kg b.i.d. for 10-14 days
Number of subjects: 776
Study: 11489703

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5335
Study: 9333320

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7971430

Group type: EXPERIMENTAL
Intervention: Symptom management interventions
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 2462943

Group type: COMPARATOR
Intervention: Mantle field RT
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Mantle field plus paraaortic RT
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy and RT
Number of subjects: 1579

Group type: COMPARATOR
Intervention: Total nodal irradiation
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: 3 MOPP-RT-3 MOPP
Number of subjects: 1579

Group type: COMPARATOR
Intervention: 3 ABVD-RT-3 ABVD
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: RT alone
Number of subjects: 1579

Group type: COMPARATOR
Intervention: CT
Number of subjects: 1579
Study: 1276818

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Medium-dose corticosteroids
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroids
Number of subjects: 26
Study: 31511055

Group type: EXPERIMENTAL
Intervention: Deep Water Running Interval Training (DWR-IT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 28254959

Group type: EXPERIMENTAL
Intervention: Telephone-supported cCBT (MoodGYM)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Minimally supported cCBT (MoodGYM)
Number of subjects: 369
Study: 26095653

Group type: EXPERIMENTAL
Intervention: sIgE to Ara h 6
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: sIgE to Ara h 2 and Ara h 6 together
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: sIgE to Ara h 8
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nonroasted peanut
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Roasted peanut
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Component‐resolved diagnostics
Number of subjects: 102
Study: 23529704

Group type: EXPERIMENTAL
Intervention: GDF‐15 concentrations
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Change in GDF‐15 concentrations
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Baseline GDF‐15 concentrations
Number of subjects: 1817
Study: 21948693

Group type: EXPERIMENTAL
Intervention: Physical exercise group (PEG) - 60 minutes of supervised exercise twice a week for 8 weeks
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control usual care group (UCG)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Physical exercise group (PEG)
Number of subjects: 231
Study: 18834820

Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21597981

Group type: EXPERIMENTAL
Intervention: Suppression condition
Number of subjects: 58

Group type: COMPARATOR
Intervention: No Suppression condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 58
Study: 15756184

Group type: EXPERIMENTAL
Intervention: Combination of morphine, bupivacaine, and epinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and epinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative analgesic injections
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative analgesic injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative treatment medication
Number of subjects: 50
Study: 14677308

Group type: EXPERIMENTAL
Intervention: Quick Liberatory Rotation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Semont Technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Parnes technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Natural evolution (untreated patients)
Number of subjects: 300
Study: 10214482

Group type: EXPERIMENTAL
Intervention: 30 mg intramuscular ketorolac upon surgical closure and every 6 hours for 36 hours and narcotic analgesics as needed (PRN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Only narcotic analgesics as needed
Number of subjects: 53
Study: 7793999

Group type: EXPERIMENTAL
Intervention: UFT (400 or 600 mg/body per day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non UFT group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UFT group
Number of subjects: 78
Study: 2191728

Group type: EXPERIMENTAL
Intervention: 100 dB SPL tones
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 75 dB tones
Number of subjects: 67
Study: 436356

Group type: EXPERIMENTAL
Intervention: Xipamide
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 3

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 3
Study: 11605931

Group type: EXPERIMENTAL
Intervention: rapacuronium (1.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: cis-atracurium (0.2 mg/kg)
Number of subjects: 20
Study: 31021896

Group type: EXPERIMENTAL
Intervention: Self-paced walking (6MW)
Number of subjects: 11
Study: 31481980

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training Group (VRTG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Cognitive Rehabilitation Group (TCRG)
Number of subjects: 100
Study: 30201675

Group type: EXPERIMENTAL
Intervention: Tension and trauma release exercises (n = 9) for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Discussion group controls (n = 9) for 6 weeks
Number of subjects: 18
Study: 27250713

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo low-level laser therapy (LLLT)
Number of subjects: 20
Study: 25419703

Group type: EXPERIMENTAL
Intervention: E-cigarette use (EC use)
Number of subjects: 956
Study: 23170867

Group type: EXPERIMENTAL
Intervention: Assimilated Turkish immigrant
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Integrated Turkish immigrant
Number of subjects: 340

Group type: COMPARATOR
Intervention: Neutral target
Number of subjects: 340
Study: 19837071

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg, morning and evening)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pantoprazole (20 mg in the morning and placebo in the evening)
Number of subjects: 160
Study: 17531193

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 142
Study: 15714291

Group type: EXPERIMENTAL
Intervention: Nutrient intake during the marathon (fluid, carbohydrate, energy, sodium)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sodium intake
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight loss during the marathon
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Running time
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nutritional recommendations compliance
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Risk of overhydration
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Correlation of body composition and race experience with performance
Number of subjects: 42
Study: 11928041

Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Abdominal Wall Lifting Technique (AWLT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups (including CO2, helium, AWLT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Helium insufflation and AWLT
Number of subjects: 33
Study: 9527781

Group type: EXPERIMENTAL
Intervention: Indinavir sulfate 400 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Indinavir sulfate 800 mg
Number of subjects: 21
Study: 8544974

Group type: EXPERIMENTAL
Intervention: Cigarette smoking with nicotine levels of < 0.1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cigarette smoking with nicotine levels of 0.6 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cigarette smoking with nicotine levels of 1.0 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cigarette smoking with nicotine levels of 2.1 mg
Number of subjects: 12
Study: 2404478

Group type: EXPERIMENTAL
Intervention: Dietary treatment leading to normalization of hemoglobin A1 value to 7.0% +/- 0.3%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dietary treatment with persistent hyperglycemia (hemoglobin A1 value, 10.7% +/- 0.7%)
Number of subjects: 42
Study: 698650

Group type: EXPERIMENTAL
Intervention: Nasogastric suction
Number of subjects: 58

Group type: COMPARATOR
Intervention: No nasogastric suction
Number of subjects: 58
Study: 30646965

Group type: EXPERIMENTAL
Intervention: Gabapentin (accumulating dose of 45 to 63 mg/kg/day, dependent on age) as add-on to morphine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo as add-on to morphine
Number of subjects: 66
Study: 28266905

Group type: EXPERIMENTAL
Intervention: Pictorial messages depicting health effects, appearance damage, or immediate risks
Number of subjects: 568

Group type: COMPARATOR
Intervention: Text-only messages
Number of subjects: 568
Study: 26202161

Group type: EXPERIMENTAL
Intervention: Rheumates@Work (R@W) program
Number of subjects: 64
Study: 23866311

Group type: EXPERIMENTAL
Intervention: Be the Best You Can Be (BtBYCB) program
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Usual Personal, Social, and Health Education classes
Number of subjects: 1333
Study: 20886228

Group type: EXPERIMENTAL
Intervention: Passive stretching
Number of subjects: 16
Study: 19501784

Group type: EXPERIMENTAL
Intervention: 100 kcal snack packs
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard size packages of snacks
Number of subjects: 59
Study: 17035446

Group type: COMPARATOR
Intervention: Tiotropium (placebo-controlled trial)
Number of subjects: 1235
Study: 12835212

Group type: EXPERIMENTAL
Intervention: Pacemaker programmed to 60 bpm
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pacemaker turned off
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prolonged follow-up with pacemakers turned off
Number of subjects: 150
Study: 10373062

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (5 microg/kg/day), n = 22
Number of subjects: 47

Group type: COMPARATOR
Intervention: No rhG‐CSF, n = 25
Number of subjects: 47
Study: 8901839

Group type: EXPERIMENTAL
Intervention: Pro25 allele presence in patients with myocardial infarction
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Pro25 allele presence in control subjects
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Pro25 allele presence in relation to hypertension
Number of subjects: 1192
Study: 1929514

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (placebo) nebulisation
Number of subjects: 21
Study: 6750532

Group type: EXPERIMENTAL
Intervention: Acyclovir therapy (5 to 10 mg/kg/8 hours, 60 minutes intravenous infusions, three times a day for 6 or 11 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acyclovir therapy
Number of subjects: 16
Study: 31256068

Group type: EXPERIMENTAL
Intervention: Walking exercise (6 min standardized walking test)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition (duration-matched quiet rest)
Number of subjects: 35
Study: 29072242

Group type: EXPERIMENTAL
Intervention: EndoVac system (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional needle irrigation (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ozonated water (OW) + EDTA (n = 20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NaOCl + EDTA (n = 20)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control, n = 10)
Number of subjects: 50
Study: 26153199

Group type: EXPERIMENTAL
Intervention: Direct Observation of Procedural Skills (DOPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine evaluation method
Number of subjects: 0
Study: 24709786

Group type: EXPERIMENTAL
Intervention: Postisometrical relaxation group (PIR group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Static stretching combined with stabilizing exercise group (SE/SS group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stabilizing exercise group (SS group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 94
Study: 21478189

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab 3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab 6 mg/kg
Number of subjects: 0
Study: 19481433

Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV with leakage during inspiration only (setting II)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV with leakage during inspiration and expiration (setting III)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV (setting II)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV (setting III)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Volume-limited NPPV
Number of subjects: 14
Study: 17032159

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy plus treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 0
Study: 12751133

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Number of subjects: 20
Study: 10946861

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg twice daily orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg x h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined E2 and GHRP-2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined treatment with E2 and GHRP-2
Number of subjects: 10
Study: 9506796

Group type: EXPERIMENTAL
Intervention: Glycogen Depletion Exercise (GDE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no glycogen depletion)
Number of subjects: 11